Transmission-blocking vaccines: uses and current status of development.
about
Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?Arbovirosis and potential transmission blocking vaccinesPlasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmissionThe chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferencesSaccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice.Suppressive effect of azithromycin on Plasmodium berghei mosquito stage development and apicoplast replicationA role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection.Identification of a major rif transcript common to gametocytes and sporozoites of Plasmodium falciparum.Current status of malaria and potential for control.Cloning, expression and transmission-blocking activity of anti-PvWARP, malaria vaccine candidate, in Anopheles stephensi mysorensis.Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.Development of vaccines against human parasitic diseases: tools, current status and perspectives.Identification of novel Plasmodium gallinaceum zygote- and ookinete-expressed proteins as targets for blocking malaria transmission.Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunizationCurrent developments in malaria transmission-blocking vaccines.Infection with Plasmodium berghei boosts antibody responses primed by a DNA vaccine encoding gametocyte antigen Pbs48/45.Towards a blood-stage vaccine for malaria: are we following all the leads?Population dynamics of sporogony for Plasmodium vivax parasites from western Thailand developing within three species of colonized Anopheles mosquitoes.Carboxypeptidases B of Anopheles gambiae as targets for a Plasmodium falciparum transmission-blocking vaccine.Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine.Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.Molecular characterization of the carboxypeptidase B1 of Anopheles stephensi and its evaluation as a target for transmission-blocking vaccines.Single-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response.Evaluation and optimization of membrane feeding compared to direct feeding as an assay for infectivity.Analysis of von Willebrand factor A domain-related protein (WARP) polymorphism in temperate and tropical Plasmodium vivax field isolates.Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection.Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria.Parasite infectivity and immunity to Plasmodium falciparum gametocytes in Gambian children.Monoclonal antibody against the Plasmodium falciparum chitinase, PfCHT1, recognizes a malaria transmission-blocking epitope in Plasmodium gallinaceum ookinetes unrelated to the chitinase PgCHT1.Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana.The roles of the glycosylphosphatidylinositol anchor on the production and immunogenicity of recombinant ookinete surface antigen Pbs21 of Plasmodium berghei when prepared in a baculovirus expression system.Optimized in vitro production of Plasmodium vivax ookinetes.Development of a method for the in vitro production of Plasmodium vivax ookinetes.Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.Hap2, a novel gene in Babesia bigemina is expressed in tick stages, and specific antibodies block zygote formation.Prevention and Control Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector Mosquitoes-Current Updates.
P2860
Q24805493-107C0D94-35C0-47A6-993D-6C47971E40CCQ27468657-4E3D870D-5054-481C-901C-0DA40170E32EQ27974514-0B523514-5A7E-45DF-9942-3D86CB8919BBQ30041470-46B593AF-0D3D-4EA1-AB7B-6E072447C057Q33747301-CFB8FCB7-2F50-4D0F-863E-481A1EF13871Q33759041-236669C4-B1E2-486A-898D-562DD2EF26FCQ33784968-8CFCD06B-2729-42E7-BBF1-270B6E505FA1Q33934212-62E7A114-1E8C-423A-AE9F-880A8F84A539Q33975652-8800C0F1-FC3D-4FE8-B177-D47973A73EA4Q33998171-8E7000A0-E238-495A-8C9C-D63A5DFFBC62Q34008562-0836C5AF-3D29-422A-94DD-99DCD6061F00Q34074704-9EF26D5C-D9E2-472D-9650-7E4FF0330AF6Q34116333-A728C641-1B17-4B73-A5BB-3DE90BE75082Q34119427-663991AD-6533-45D8-ADCE-B47C989BCEAEQ34451883-52E943CB-2DCE-4E49-95D0-8D1BE3DCB7A7Q34492582-DA6346C5-C0F2-44F2-9385-10A033B092E0Q34572160-59637BB1-09C4-4079-99C4-86D92A2E162AQ35013256-7D46EAC4-886B-4249-AA41-71B883FBD1FCQ35783861-8BEEC1D0-F9E9-4803-B1F0-FD94E1364416Q35867612-BEA93C9B-8695-4656-81F8-E1ED4A6E770EQ35947113-B8FB08C0-148C-4F95-BDD3-4DCBBC6710A4Q36079818-3CEBC38A-BC5A-4B70-902C-BABCE9297D04Q36911522-8510379C-ED46-495B-88B3-00E214B091EDQ36998403-7622C922-2DCD-4F19-A76D-D604AD6148E0Q37092966-4EE8AAD4-1D6F-482E-B879-1616EBA52604Q37259973-B1909CAB-E3C8-479E-B590-9A564E913424Q37451022-4914A8EA-BD70-42F0-A21E-5B21FCFED9CCQ37546481-E3493587-EB3F-4BE2-80CA-FC5AD3AAC14FQ38977779-6EE904F6-CF6C-4594-9DDE-116209AE05F3Q39159827-0AE3B3CD-A6DD-4D3E-A79F-2E801C67013BQ40110842-DE740185-2C0E-4E44-82B6-8911F1AC38C7Q40851909-4A4B47CA-15FE-4D6B-ADC9-55C0B890FC03Q41668687-A9BEB3A9-0F71-497D-932E-8237A5BCA1A0Q43727136-BAE3B289-61A6-47EE-A76A-61950ABB69F9Q44169836-5EB33557-D566-40E3-AE06-B3029E27D968Q46262566-3C0A7D61-3F87-4FF7-970D-49E3F3CB53CFQ50277220-957B5E2C-49D9-4CA7-A0D7-D15DA9527157
P2860
Transmission-blocking vaccines: uses and current status of development.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Transmission-blocking vaccines: uses and current status of development.
@en
Transmission-blocking vaccines: uses and current status of development.
@nl
type
label
Transmission-blocking vaccines: uses and current status of development.
@en
Transmission-blocking vaccines: uses and current status of development.
@nl
prefLabel
Transmission-blocking vaccines: uses and current status of development.
@en
Transmission-blocking vaccines: uses and current status of development.
@nl
P1476
Transmission-blocking vaccines: uses and current status of development.
@en
P2093
P304
P356
10.1016/S0020-7519(96)00148-8
P577
1997-02-01T00:00:00Z